Deferred License Revenue (Details) - USD ($)	1 Months Ended					3 Months Ended			9 Months Ended		12 Months Ended
	May 31, 2022	Jun. 30, 2021	Sep. 30, 2020	Jan. 31, 2020	Oct. 31, 2014	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2016	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Contract Liabilities, which are included in deferred license revenue						$ 533,000			$ 533,000			$ 4,331,000
Triferic Inventory | SEC Schedule, 12-09, Reserve, Inventory
Disaggregation of Revenue [Line Items]
Inventory reserve, period increase (decrease)						1,100,000
Baxter Healthcare Organization
Disaggregation of Revenue [Line Items]
Term of agreement					10 years
Upfront payment					$ 20,000,000
Recognized deferred revenue							$ 1,500,000
Wanbang Biopharmaceutical
Disaggregation of Revenue [Line Items]
Upfront payment											$ 4,000,000
Recognized deferred revenue						2,200,000
Wanbang Biopharmaceutical | Triferic Inventory
Disaggregation of Revenue [Line Items]
Inventory reserve, increase in gross profit						1,100,000
Wanbang Biopharmaceutical | Triferic Inventory | SEC Schedule, 12-09, Reserve, Inventory
Disaggregation of Revenue [Line Items]
Inventory reserve, period increase (decrease)						1,100,000
Sun Pharma Agreements
Disaggregation of Revenue [Line Items]
Upfront payment				$ 100,000
Recognized deferred revenue						2,500		$ 7,500	2,500	$ 7,500
Contract Liabilities, which are included in deferred license revenue						62,500			62,500			70,000
Jeil Pharma Agreements
Disaggregation of Revenue [Line Items]
Upfront payment			$ 200,000
Recognized deferred revenue						5,200		15,600	5,200	15,600
Contract Liabilities, which are included in deferred license revenue						400,000			400,000			400,000
Milestone consideration	$ 200,000
Drogsan Agreements
Disaggregation of Revenue [Line Items]
Upfront payment		$ 150,000
Recognized deferred revenue						3,750		$ 11,250	3,750	$ 11,250
Contract Liabilities, which are included in deferred license revenue						$ 100,000			$ 100,000			$ 100,000